EU Plan to Manage Coronavirus Mutations

EU Plan to Manage Coronavirus Mutations
share Share

HERA Incubator, a new bio-defence preparedness programme in the EU, will receive €150 million to manage novel coronavirus mutations and ensure access to effective vaccines against them.

 

You might also like: The European Commission has called member states to accelerate the roll-out of their vaccination programmes. The aim is to have vaccinated 70% of the adult population by summer 2021.
Read more.

 

The programme is a pilot for the EU Health Emergency Preparedness and Response Authority (HERA) and will incorporate permanent structures for risk modelling, threat assessment and surveillance. It will facilitate not only management of virus variants but also adaption of existing/new advance purchase agreements as well as regulatory approval of vaccines (including COVID-19 vaccines) and manufacturing infrastructures.


Through Horizon 2020, a new EU-wide vaccine trial network called
VACCELERATE will be established supported by open data sharing, cohorts studies and vaccine trials. As of January 2021, the network, led by University-Hospital Köln, assessed over 180 vaccine trial sites (hospitals, primary care, paediatric networks, etc.) in 30 European countries on their capacity to perform vaccine trials. VACCELERATE will receive a €12 million grant to support the rapid establishment of a clinical research network.


Currently, 26 partners in 16 EU states participate in the VACCELERATE project together with five associated countries. A Stakeholder Working Group (SWG) of the network will include the European Medicines Agency (EMA), national authorities, the European Centre for Disease Prevention and Control (ECDC), and other partners. The overall budget stands at €150 million, including €30 million from Horizon 2020 and €120 million from Horizon Europe. To date, the EU mobilised at least €350 million to support coronavirus vaccine development.


Besides the VACCELERATE, HERA Incubator also foresees further development of several existing projects, including
ELIXIR-CONVERGE, the European Virus Archive (EVAg), the Versatile Emerging Infectious Disease Observatory (VEO) and others.

 

Source: European Commission

«« Over $4.3B Pledged by G7 in COVID-19 Fight, More Funds Needed


Burnout in U.S. Nurses: Risks and Consequences »»

Published on : Thu, 18 Feb 2021



Related Articles
IBM & Moderna Collaborate for Better COVID-19 Vaccine Management

The vaccine manufacturer Moderna and IBM, a technology company, will work together on implementation of technologies such... Read more

First COVID-19 Vaccine Trial in Children

Moderna has begun testing its COVID-19 vaccine in children ages 6 months to less than 12 years. This is the first such... Read more

COVID-19 Vaccine Passports Are Coming to EU

The European Commission has officially proposed the creation of the EU's ‘COVID-19 passport’ and is planning to have introduced the... Read more

European Commission, Horizon 2020, COVID-19 vaccine trial, COVID-19 vaccines’ supply chain, Horizon Europe, vaccine repurposing, VACCELERATE, Health Emergency Preparedness and Response Authority (HERA) EU Plan to Manage Coronavirus Mutations

No comment


Please login to leave a comment...